Erythropoietin is the major regulating blood flow hormone which can be effect on hematopoiesis of premature infants. The aim of this study was to examine the effectiveness of intravenous recombinant erythropoietin regimen associated with oral iron in hematopoiesis of premature infants. This is a randomized clinical trial that has been done on 80 (40 persons in each group) very low and premature infants. First group received intravenous recombinant erythropoietin (with 400 units per kg weight in day (3 days in week)) associated with iron drip and second group as control group iron administrated only. All information were entered in a checklist and analyzed by statistical methods in SPSS.16. In case group 62.5% and in control group 60% were boy. The average weight of cases was 1273.8± 198.4 gr and controls were 1223.8± 217.5 gr. The injection of erythropoietin could be significantly prevent the decreasing of hemoglobin and ferritin and leads to increase in reticulocytes levels in cases but not have significantly on Iron level. Results showed that injection of erythropoietin in premature infants deal to increasing reticulocyte, Hb and ferritin levels in case group and the results was similar with studies in other places.
Erythropoietin, iron therapy, VLBW infant, hematopoiesis